Beijing Huasu Wins NMPA Clinical Trial Approval for Methylphenidate ER Chewable Tablets, First Domestic Generic for ADHD Treatment
Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of Beijing Centergate Technologies (SHE: 000931), has received...
Company
Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis
Novartis (NYSE: NVS) announced positive topline results from its Phase III REMODEL-1/-2 clinical trials of...
SYS6010 Earns Third NMPA Breakthrough Therapy Designation, Advancing CSPC Innovation Pharmaceutical’s EGFR ADC in R/M HNSCC
CSPC Innovation Pharmaceutical Co., Ltd. (SHE: 300765) announced that SYS6010, its epidermal growth factor receptor...
Huadong Medicine and Heidelberg Pharma Expand ADC Collaboration to Advance Next-Generation Bispecific Conjugates
Huadong Medicine (SHE: 000963) announced that it signed a new additional collaboration agreement with its...
Sino Biopharmaceutical’s CTTQ Grants Cipla Rights to TQB2102 HER2 ADC in Emerging Markets for Up to USD 123 Million
Sino Biopharmaceutical (HKG: 1177) announced that its subsidiary, Chia Tai Tianqing (CTTQ), entered into an...
GenSci161 Wins NMPA Clinical Trial Acceptance for CTD-ILD, Expanding Bispecific Antibody Pipeline of Changchun High & New Technology
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its novel bispecific...
Simcere Zaiming Licenses SIM0660 Trispecific Antibody to Roche in Up to USD 1.53 Billion Oncology Deal
Simcere Zaiming Pharmaceutical, an oncology-focused innovative drug company under Simcere Pharmaceutical (HKG: 2096), announced that...
Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
China’s Shanghai RAAS (SHE: 002252) announced that its candidate SR604 has been included by the...
Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
Eisai Co., Ltd. (TYO: 4523) announced that LEQEMBI IQLIK, a subcutaneous auto-injector formulation of lecanemab,...
Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced that it has initiated a Phase I...
Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent
Johnson & Johnson MedTech and Jiangsu CED Medical Technology Co., Ltd. (“CED Medical”) have signed...
CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China
CSPC Pharmaceutical Group (HKG: 1093) announced that the Phase I clinical trial of SYH2092, an...
Ocumension Therapeutics Completes First-Patient Enrollment of OT-202 Phase III Trial for Dry Eye Disease in China
Ocumension Therapeutics (HKG: 1477) announced that OT-202, the company’s first-in-class candidate for the treatment of...
Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform
Eli Lilly (NYSE: LLY) and Merida Biosciences, a biotechnology company advancing a new class of...
Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug
China-based Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) announced plans to invest RMB 40 million...
WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies
WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE’s...
Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a...
Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400...
Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline
Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand...
Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)...